The publication explores the growing mismatch between the EU’s economic governance framework and the long-term investment needs of the pharmaceutical and healthcare sectors.
The publication explores the growing mismatch between the EU’s economic governance framework and the long-term investment needs of the pharmaceutical and healthcare sectors. It highlights how the European Semester, while effective in promoting fiscal discipline and short-term economic stability, tends to discourage sustained investment in research, innovation, manufacturing capacity, and supply chain resilience. As a result, Europe risks losing competitiveness in life sciences and becoming more dependent on external suppliers for critical medicines. The book argues that reforming the European Semester to incorporate multi-year planning, strategic healthcare investments, and stronger cross-border coordination would help strengthen Europe’s pharmaceutical ecosystem, improve health security, and support long-term economic and public health resilience